487 related articles for article (PubMed ID: 34077939)
21.
Carlsen EA; Johnbeck CB; Binderup T; Loft M; Pfeifer A; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2020 Oct; 61(10):1491-1497. PubMed ID: 32111685
[TBL] [Abstract][Full Text] [Related]
22. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A
Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
25. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
27. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
28. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer.
Gild ML; Kumar S; Fuchs TL; Glover A; Sidhu S; Sywak M; Tsang V; Gill AJ; Robinson BG; Schembri G; Clifton-Bligh RJ; Hoang J
Endocr Pract; 2024 Mar; 30(3):218-224. PubMed ID: 38103829
[TBL] [Abstract][Full Text] [Related]
29. The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors.
Meirovitz A; Shouchane-Blum K; Maly A; Bersudski E; Hirshoren N; Abrams R; Popovtzer A; Orevi M; Weinberger J
J Cancer Res Clin Oncol; 2021 May; 147(5):1335-1340. PubMed ID: 33598797
[TBL] [Abstract][Full Text] [Related]
30. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
[TBL] [Abstract][Full Text] [Related]
31. Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.
Roden AC; Rakshit S; Johnson GB; Jenkins SM; Mansfield AS
Front Oncol; 2022; 12():823667. PubMed ID: 35198446
[TBL] [Abstract][Full Text] [Related]
32.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy.
Park H; Subramaniam RM
PET Clin; 2023 Apr; 18(2):223-231. PubMed ID: 36585338
[TBL] [Abstract][Full Text] [Related]
34.
Delpassand ES; Ranganathan D; Wagh N; Shafie A; Gaber A; Abbasi A; Kjaer A; Tworowska I; Núñez R
J Nucl Med; 2020 Jun; 61(6):890-896. PubMed ID: 31924723
[TBL] [Abstract][Full Text] [Related]
35. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
36.
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
[No Abstract] [Full Text] [Related]
37. Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease.
Sharma A; Navaz AJ; Pandey MK; Parent EE
Clin Nucl Med; 2022 Feb; 47(2):137-139. PubMed ID: 34690295
[TBL] [Abstract][Full Text] [Related]
38. Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT.
Kunz WG; Eschbach RS; Stahl R; Kazmierczak PM; Bartenstein P; Rominger A; Auernhammer CJ; Spitzweg C; Ricke J; Cyran CC
Cancer Imaging; 2018 Sep; 18(1):34. PubMed ID: 30236163
[TBL] [Abstract][Full Text] [Related]
39. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
[TBL] [Abstract][Full Text] [Related]
40. Solitary Contralateral Adrenal Metastasis of Renal Cell Carcinoma: 68Ga-DOTATATE PET/CT Findings.
Filizoglu N; Ozguven S
Clin Nucl Med; 2022 Jan; 47(1):e41-e42. PubMed ID: 34132679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
